*Breast Cancer Research and Treatment* **66:** 273–274, 2001.
© 2001 *Kluwer Academic Publishers. Printed in the Netherlands.*

# Author index, Volume 66


Ahlborn, T.E., 111
Alba, E., 33
Albonico, G., 135
Alexander, M., 89
Allred, D.C., 219
Alonso, L., 33
Amano, J., 165
Arias, V., 249
Avis, I., 219
Baak, J.P. A., 203
Bacoti, D., 239
Baroni, T., 67
Bay, B.-H., 265
Bedrick, E., 25
Bellamy, C.O.C., 193
Bendit, I., 249
Bergomi, S., 101
Bianco, C., 1
Bjarnason, G.A., 123
Bloch, R., 239
Body, G., 17
Bonilla, F., 185
Bontenbal, M., 83
Borgen, P., 239
Bornstein, R., 227
Botti, G., 211
Bougnoux, P., 17
Cameron, D.A., 193
Cariello, A., 135
Carli, L., 67
Chang, R.-F., 51
Chen, D.-R., 51
Chow, V.T.-K., 265
Crispo, A., 211
Crumpton, T.L., 143
D'Aiuto, G., 211
de Bellis, G., 211
de Jong, J.S., 203
de Marco, M., 211
del Giglio, A., 249
Descamps, P., 17
Diamond, J., 59
Dietze, E.C., 41
Dixon, J.M., 193
Dixon, J.M., 9
Dominguez, G., 185
Dong, C., 171
Ebert, A., 1
España, P., 185
Fabbrocini, G., 211
Fallowfield, L.J, 73
Fellowes, D., 73
Ferretti, S., 135
Festa, A., 101
Floch, O.L., 17
Fonseca, F.L.A., 249
Franssen, E., 123
Frost, F.J., 25
Fruehauf, J.P., 227
Fujimori, M., 165
Gallego, I., 185
Garcia, J.M., 185
Giovannini, E., 67
Giralt, S., 249
Gollub, M., 239
Gupta, M.S., 147
Hellman, S., 179
Hemminki, K., 171
de Heus, G., 83
Houghton, J., 73
Hubert, B., 17
Hudis, C., 239
de Iasio, M.G., 135
Ito, Y., 95
Jin, R., 265
Jurišić, V., 255
Kabashima, A., 159
Kano, Y., 165
Khan, N.I., 1
Kinoshita, J., 159
Kitamura, K., 159
Konjević, G., 255
Kraemer, F.B., 111
Kunde, T., 25
Kuo, W.-J., 51
Kurian, K.M., 9
Lansac, J., 17
Lee, C.C., 51
Lee, J.-E., 147
Lefranc, T., 17
Leonard, R.C.F., 193
Li, C., 111
Li, K.-T., 227
Ligueros, M., 239
Lippman, M.E., 279
Liu, J., 111
Lopes, F., 249
Love, C.D.B., 193
Madarnas, Y., 123
Maestri, I., 135
Maini, C.L., 101
Manhani, A.R., 249
Manhani, R., 249
Marquez, A., 33
Marret, H., 17
Marson, L.P., 9
Martínez, A., 219
Matsuura, N., 95
Matteuzzi, M., 135
McDougal, A., 147
McLaren, C.E., 227
McMillan, G., 25
Mehta, R.S., 227
Miller, W.R., 193
Miller, W.R., 9
Miramón, J., 33
Moasser, M.M., 239
Montella, M., 211
Morrow, D., 147
Mulshine, J.L., 219
Nakamura, T., 165
Navarro, A., 185
Nenci, I., 135
Nguyen, K.P., 227
Nicoletti, A.G.B., 249
Noguchi, S., 95
Norton, L., 239
Novaes, M., 249
Parker, R.J., 227
Pasqualoni, R., 101
Passos-Coelho, J.L., 59
Pedriali, M., 135

Perrotin, F., 17
Petersen, H.V., 25
Pizzorusso, M., 211
Provencio, M., 185
Querzoli, P., 135
Ramamoorthy, K., 147
Rea, S., 101
Reidenberg, M.M., 239
Ribelles, N., 33
Rinaldi, R., 135
Romani, R., 67
Rosi, G., 67
Rueda, A., 33
Ruiz, I., 33
Rulli, A., 67
Saeki, H., 159
Safe, S.H., 147
Salomon, D.S., 1
Sanchez, A., 185
Sasaki, T., 165
Saunders, C.M, 73
Sawka, C.A., 123
Sciuto, R., 101
Seewaldt, V.L., 41
Seidler, F.J., 143
Seidman, A.D., 239
Semprebene, A., 101
Sevilla, I., 33
Seynaeve, C., 83
Silva, A.L., 59
Silva, J., 185
Silva, J.M., 185
Silva, M.R.G., 59
Sklarin, N., 239
Slotkin, T.A., 143
Smith, H., 193
Smith, L., 219
Smorenburg, C.H., 83
Soares, H.P., 249
Sonenberg, M., 239
Spužić, I., 255
Stidley, C.A., 25
Sugimachi, K., 159
Sun, Y., 1
Takeda, T., 95
Talesa, V., 67
Tamburini, M., 211
Tan, P.-H., 265
Tanaka, S., 159
Taniguchi, S., 165
Tollestrup, K., 25
Treston, A.M., 219
van der Valk, P., 203
van Diest, P.J., 203
Van Poznak, C., 239
Van Zee, K., 239
Verweij, J., 83
Vos, M.D., 219
Wechselberger, C., 1
de Wit, R., 83
Yao, T.-J., 239
Yazawa, K., 165
Yee, L., 41
Yu, I.-R., 227
Zatta, S.M., 249
Zhou, J., 219
van Zuylen, C., 83

*Breast Cancer Research and Treatment* **66:** 275–278, 2001.
© 2001 *Kluwer Academic Publishers. Printed in the Netherlands.*

# Subject index, Volume 66

186Re-HEDP
  metastatic bone pain treatment in breast cancer patients 101-109
89Sr
  metastatic bone pain treatment in breast cancer patients 101-109
adjuvant therapy
  as a prognostic factor in metastatic breast cancer 33-39
anaerobic bacteria
  as delivery system for gene therapy 165-170
anthracyclines
  adjuvant therapy as a prognostic factor in metastatic breast cancer 33-39
antitumorigenic
  activity in the breast 147-157
apoptosis
  and growth factors in invasive breast cancer 201-208
aromatase inhibitors
  in locally advanced and large operable breast cancer 191-199

bcl-2
  and the rate of apoptosis in invasive breast cancer 201-208
*Bifidobacterium longum*
  as a delivery system for gene therapy 165-170
  body mass index as independent predictive factor of local recurrence after conservative treatment 17-23
  size biasing of medical oncologists in their treatment 123-133
BRCA1
  associated with Fas ligand expression in hereditary breast carcinoma 95-100
  deleted breast cancer in young women 135-142
  breast cancer angiogenesis and the effect of tamoxifen 9-15
  cell growth abrogation by blocking ERK activation 111-121
  costs of health care in a MCO 25-31
  carcinogenesis hnRNP-A2/B1 as a marker 217-224
  neoplasms after chemotherapy 249-254
breast-conserving therapy
  body mass index as independent predictive factor of local recurrence 17-23

cell death
  in invasive breast cancer patients 201-208
chemotherapy
  clinical outcome for patients with *in vitro* EDR assay results 225-237
  dosing of the large woman with breast cancer 123-133
  with anthracycline as a prognostic factor in metastatic breast cancer 33-39
*CK-19* expression
  in breast cancer patients 249-254
clinical stage
  of disease prior to therapy and NK cell dysfunction with alterations in LDH 255-263
computer-aided diagnosis
  of breast tumor in medical ultrasonic images 51-57
costs
  of breast cancer health care in a MCO 25-31
co-variance features
  in the computer-aided diagnosis of breast tumor 51-57
Cripto-1
  identification in human milk 1-7
cyclin D1
  assessed by serial biopsies in the treatment of metastatic breast cancer 239-248
Cytokeratin 20
  as a marker for occult breast cancer cell detection 59-66

D17S786
  deleted breast cancer in young women 135-142
D17S855
  deleted breast cancer in young women 135-142
data mining
  with decision trees for computer-aided diagnosis of breast tumor 51-57
decision tree

for computer-aided diagnosis of breast tumor 51-57
disease free survival rate
of patients with breast cancer with VEGF-C 159-164
dose intensity
in the treatment of the large woman with breast cancer 123-133
drug resistance
and breast cancer survival 225-237

early detection marker
differential hnRNP expression in breast cancer 217-224
early-onset breast cancer
biophenotypes and survival after deletion with BRCA1 and TP53 135-142
education
reducing diagnostic delays in breast cancer treatment in Southern Italy 209-215
endocrine
therapy in locally advanced and large operable breast cancer 191-199
ERK
blocking of activation causing abrogation of OM growth inhibitory activity 111-121

Fas
ligand expression in *BRCA-1*-associated hereditary breast carcinoma 95-100

gene
expression in human breast carcinoma 67-72
therapy *Bifidobacterium longum* as a delivery system 165-170
glutathione
levels in breast cancer tissues 67-72
glyoxalase
I
in normal and breast cancer tissues 67-72
II
in normal and breast cancer tissues 67-72
goserelin
as adjuvant therapy for breast cancer 73-81
gossypol
in the treatment of metastatic breast cancer 239-248
growth factor receptors
and apoptosis in invasive breast cancer 201-208

hereditary breast carcinoma
Fas ligand expression associated with *BRCA1* 95-100
histological grade
correlating with MT-1F expression in breast carcinoma 265-272
4-HPR
resistance in HMEC's 41-30
human milk
identification of Cripto-1 1-7
hypoxia
gene therapy for solid tumors 165-170

immunohistochemistry
expression of MT-1F in breast cancer 265-272
overexpresion of hnRNP in breast cancer 217-224
*in vitro* assay
results for patients with breast carcinoma associated with clinical outcome after chemotherapy 227-238
intermediate endpoint marker
hnRNP expression in breast cancer 217-224

keratin/analysis
*CK-19* expression in breast cancer patients 249-259

LDH activity
in PBL of breast cancer patients 255-263
letrozole
in locally advanced and large operable breast cancer 191-199
local recurrence
body mass index as independent predictive factor 17-23
lymphatic vessel invasion
significant correlation with the expression of VEGF-C 159-164

mammary epithelial cells
and the role of Cripto-1 in human milk 1-7
pRB expression and retinoid-mediated growth arrest and apoptosis 41-50
managed care organisation (MCO)
the excess of costs of breast cancer health care 25-31
medical delay
in breast cancer treatment in Southern Italy 209-215

profession training programs for medically underserved status 209-215
medically underserved
status associated with diagnostic delays in breast cancer treatment in Southern Italy 209-215
metallothionein
1F expression in breast cancer 265-272
methylglyoxal
levels in breast cancer tissues 67-72
microvessel counts
measuring the effect of tamoxifen in breast tumour 9-15
minimal residual disease
Cytokeratin 20 as a reliable molecular cell detection marker in hematological tissues 59-66
multivariate analysis
of breast cancer local recurrences 17-23

NK cell activity
and LDH alterations in PBL of breast cancer patients 255-263
novel chemotherapeutics
in the treatment of metastatic breast cancer 239-248

obesity
coexisting with breast cancer 123-133
occult carcinoma cells
Cytokeratin 20 as a detection marker in hematological tissues 59-66
oncostatin M
abrogation of growth inhibitory activity by blocking ERK activation 111-121
overall delay
of breast cancer treatment in Southern Italy 209-215
oxidative stress
by xanthine effects on MDA-MB-231 143-146

patient delay
of breast cancer treatment in Southern Italy 209-215
p53 gene
and the relation of apoptosis in invasive breast cancer patients 201-208
mutations in relation to p73 overexpression in breast cancer 183-190
p73 gene
overexpression in breast cancer 183-190
p73 LOH
status of the 1p36 region in breast cancer 183-190
pain palliation
radionuclide treatment in breast cancer patients 101-109
pharmacoepidemiology
in the treatment of the large woman with breast cancer 123-133
predictive factor
of a VEGF-C positive patients 159-164
prognosis
of response of RT-PCR-based techniques for the detection of *CK-19* expression in breast cancer patients 249-254
prognostic factors
of local recurrence after conservative treatment 17-23
proliferation
in HEMC's 41-50
prospective studies
in the response to chemotherapy 249-254

radionuclide treatment
of metastatic bone pain in breast cancer 101-109
reactive oxygen
generation of species by xanthine effects on MDA-MB-231 cells 143-146
recurrence
*CK-19* expression in breast cancer patients 249-254
retinoblastoma
gene product in patients with refractory metastatic breast cancer 239-248
protein expression and retinoid-mediated growth arrest and apoptosis in HMEC's 41-50
retinoids
mediated growth arrest in HMEC's 41-50
reverse transcription polymerase chain reaction (RT-PCR)
evaluation of MT-1F expression in breast cancer 265-272

selective AhR modulators
and the inhibition of rat mammary tumor growth 147-157
side effects
of hormone therapies for breast cancer 73-81
signal transduction
abrogation of OM growth inhibitory activity 111-121
sodium nitroprusside
xanthine effects on MDA-MB-231 cells 143-146
substituted diindolylmethanes

as inhibitors of rat mammary tumor growth 147-157
survival
and *in vitro* drug response 225-237
symptoms
profiles for 'well tolerated' treatments 73-81

tamoxifen
the effect on breast tumour vascularity 9-15
tolerability of therapies for breast cancer 73-81
theophylline
evoking the generation of reactive oxygen species in human breast cancer cells 143-146
third-line treatment
of patients with metastatic breast cancer 83-87
tolerability
of hormone therapies for breast cancer 73-81
tumor markers
expression of *CK-19* in breast cancer patients 249-254
size in overall delay cases of breast cancer treatment in Southern Italy 211-217

ultrasound
computer-aided diagnosis of images 51-57

vector
*Bifidobacterium longum* for gene therapy on solid tumors 165-170
VEGF-C
clinical significance in breast cancer 159-164

xanthine derivatives
in MDA-MB-231 human breast cancer cells 143-146